Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • 2023 Diversity, Equity, & Inclusion Report
    • 2023 Industry Snapshot
    • 2022 Massachusetts Biopharma Funding Report
    • 2022 MA Life Sciences Workforce Analysis Report
    • Economic Development
    • Biopharma Startup Toolkit
    • Career Center
    • MassBioEd
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Savings and Rewards
    • Member News
    • Become a Member
    • Member Rates
    • Pay Company Dues
  • Savings & Rewards
    • MassBioEdge
  • Conference Center
    • MassBioHub
  • Programs
    • Bioversity at Southline Boston
    • State of Possible 2025 Report
    • Diversity, Equity, and Inclusion
    • Policy & Advocacy
    • Partnering Opportunities
    • MassBioDrive
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • News & Thought Leadership
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • FAQs
    • Contact Us
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Sumitomo Pharma Oncology, Inc.

Life Sciences | Drug Development
Marlborough, MA 617-674-6800 Website LinkedIn

Overview

Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer Research Unit and Oncology Clinical Development Unit, will collectively be known as Sumitomo Pharma Oncology or SMP Oncology.

SMP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common goal—advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer.
At SMP Oncology, we are relentlessly exploring novel and unique approaches to address unmet needs in oncology research and development. Through scientific persistence and a commitment to discovery, we are focused on advancing a diverse and purposeful pipeline.

Please visit https://oncology.sumitomo-pharma.com/join-our-team/current-opportunities/ to see what exciting opportunities we have available.

Company News

News

Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at American Society of Hematology 2022 Annual

Dec 15, 2022

Posted by Sumitomo Pharma Oncology, Inc.

News

Sumitomo Pharma Oncology to Present Preliminary Clinical Data Evaluating Investigational Agent TP-3654 at the 64th ASH Annual Meeting & Exposition

Nov 03, 2022

Posted by Sumitomo Pharma Oncology, Inc.

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2024 All Rights Reserved